TSHA May 2024 2.500 call
| Previous close | 0.3000 |
| Open | 0.4000 |
| Bid | 0.3000 |
| Ask | 0.6000 |
| Strike | 2.50 |
| Expiry date | 2024-05-17 |
| Day's range | 0.3000 - 0.4000 |
| Contract range | N/A |
| Volume | |
| Open interest | 435 |
ZacksWill Taysha Gene Therapies, Inc. (TSHA) Report Negative Q1 Earnings? What You Should Know
Taysha Gene Therapies (TSHA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GlobeNewswireTaysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome
RMAT designation follows FDA’s review of available safety and efficacy data from the first three patients dosed with the low dose of TSHA-102 across both REVEAL Phase 1/2 trials (adolescent/adult and pediatric) RMAT designation enables increased dialogue with the FDA to support the potential expedited development and review of TSHA-102 in clinical evaluation for Rett syndrome DALLAS, May 02, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy compan
Simply Wall St.Analysts' Revenue Estimates For Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Are Surging Higher
Shareholders in Taysha Gene Therapies, Inc. ( NASDAQ:TSHA ) may be thrilled to learn that the analysts have just...
